Portfolio company
Singular Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops single molecule detection technology for cell-free DNA analysis to provide non-invasive prenatal screening for the healthcare and genomics sectors.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Single molecule diagnostics
This company develops prenatal screening and oncology liquid biopsy tests for clinicians to identify genetic risks and monitor cancer treatments in patients.
BillionToOne
This company develops molecular diagnostic tests for prenatal screening and oncology care to help clinicians and patients identify genetic conditions and monitor cancer.
Seed, 2024
This company develops a single-molecule DNA sequencing platform for clinical diagnostics, agriculture, and biosecurity sectors.
BioSkryb
This company develops genomic amplification and sequencing systems for researchers and clinicians to analyse DNA and RNA from single cells.
Genetic Sequencing
This company develops nanopore-based technology for DNA sequencing to support researchers and clinicians in medical diagnostics and genomic analysis.
Geneseque
This company develops a single-molecule DNA sequencing technology for the life sciences sector and research partners.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
NX Prenatal
This company develops exosome-based blood tests to detect pregnancy complications for physicians and expectant mothers.